Advertisement

Iron Chelation Therapy

  • Chaim Hershko

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 509)

Table of contents

  1. Front Matter
    Pages i-viii
  2. Antonello Pietrangelo
    Pages 19-43
  3. Z. Ioav Cabantchik, Or Kakhlon, Silvina Epsztejn, Giulianna Zanninelli, William Breuer
    Pages 55-75
  4. Chaim Hershko, Gabriela Link, Abraham M Konijn
    Pages 77-89
  5. Bernard A. Davis, John B. Porter
    Pages 91-125
  6. Victor A Hoffbrand, Beatrix Wonke
    Pages 127-139
  7. Zu D. Liu, Ding Y. Liu, Robert C. Hider
    Pages 141-166
  8. Raymond J. Bergeron, Jan Wiegand, James S. McManis, William R. Weimar, Guangfei Huang
    Pages 167-184
  9. Hanspeter Nick, Agnes Wong, Pierre Acklin, Bernard Faller, Yi Jin, René Lattmann et al.
    Pages 185-203
  10. Joan L. Buss, Marcelo Hermes-Lima, Prem Ponka
    Pages 205-229
  11. Victor R. Gordeuk, Mark Loyevsky
    Pages 251-272
  12. Back Matter
    Pages 273-276

About this book

Introduction

Within the last few years, iron research has yielded exciting new insights into the under­ standing of normal iron homeostasis. However, normal iron physiology offers little protec­ tion from the toxic effects of pathological iron accumulation, because nature did not equip us with effective mechanisms of iron excretion. Excess iron may be effectively removed by phlebotomy in hereditary hemochromatosis, but this method cannot be applied to chronic anemias associated with iron overload. In these diseases, iron chelating therapy is the only method available for preventing early death caused mainly by myocardial and hepatic iron toxicity. Iron chelating therapy has changed the quality of life and life expectancy of thalassemic patients. However, the high cost and rigorous requirements of deferoxamine therapy, and the significant toxicity of deferiprone underline the need for the continued development of new and improved orally effective iron chelators. Such development, and the evolution of improved strategies of iron chelating therapy require better understanding of the pathophysiology of iron toxicity and the mechanism of action of iron chelating drugs. The timeliness of the present volume is underlined by several significant develop­ ments in recent years. New insights have been gained into the molecular basis of aberrant iron handling in hereditary disorders and the pathophysiology of iron overload (Chapters 1-5).

Keywords

Handling Malaria cancer therapy cell development evolution homeostasis iron molecular basis pathophysiology physiology proliferation therapy toxicity

Editors and affiliations

  • Chaim Hershko
    • 1
  1. 1.Hebrew University School of MedicineJerusalemIsrael

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4615-0593-8
  • Copyright Information Springer-Verlag US 2002
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-0-306-46785-1
  • Online ISBN 978-1-4615-0593-8
  • Series Print ISSN 0065-2598
  • Buy this book on publisher's site
Industry Sectors
Pharma
Materials & Steel
Chemical Manufacturing
Biotechnology
Consumer Packaged Goods
Energy, Utilities & Environment